Oral ulcers in patients treated with palbociclib: a case report

Oral ulcers in patients treated with palbociclib: a case report

Introduction: Palbociclib is an approved drug in the treatment of women with advanced or metastatic estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, breast cancer. The purpose of this article is to present the first case ever described of oral ulcers caused...

Full description

Bibliographic Details
Main Authors:	Alande Cédric, Fénélon Mathilde, Fricain Jean-Christophe
Format:	Article
Language:	English
Published:	EDP Sciences 2018-06-01
Series:	Journal of Oral Medicine and Oral Surgery
Subjects:	palbociclib ulcer breast cancer
Online Access:	https://www.jomos.org/articles/mbcb/full_html/2018/02/mbcb170064/mbcb170064.html

Similar Items

Letter to the Editor: statistics and clinical perception of patients’ reported outcomes for palbociclib and abemaciclib: a sliding doors story
by: Vittorio Gebbia
Published: (2023-04-01)

Role of palbociclib in the treatment of hormone receptor-positive HER2-negative metastatic breast cancer. Generalizing results of randomized trials and real clinical practice
by: L. G. Zhukova, et al.
Published: (2019-06-01)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
by: Alexandre Le Marouille, et al.
Published: (2021-10-01)

Palbociclib in metastatic breast cancer: current evidence and real-life data
by: Francesco Serra, et al.
Published: (2019-07-01)

Letter in Reply: indirect comparison of quality-of-life scores between patients with advanced breast cancer receiving palbociclib and abemaciclib in combination with fulvestrant
by: Ernest H Law, et al.
Published: (2023-04-01)

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
by: Hope S. Rugo, et al.
Published: (2023-06-01)

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
by: Engel-Nitz NM, et al.
Published: (2023-04-01)

Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China
by: Xinyu Wu, et al.
Published: (2023-09-01)

Palbociclib Induces Senescence in Melanoma and Breast Cancer Cells and Leads to Additive Growth Arrest in Combination With Irradiation
by: Tina Jost, et al.
Published: (2021-10-01)

Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study
by: Kadir Eser, et al.
Published: (2022-05-01)

A Substantial Response from Adding Palbociclib to Endocrine Therapy in Brain Metastasis from Hormone Receptor-Positive, HER2-Negative Breast Cancer: Case Reports
by: Atlal Abusanad, et al.
Published: (2021-03-01)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
by: Atakan Demir, et al.
Published: (2020-03-01)

Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
by: B. Porte, et al.
Published: (2020-12-01)

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
by: J. K. Kish, et al.
Published: (2018-05-01)

Glucose Metabolic Reprogramming of ER Breast Cancer in Acquired Resistance to the CDK4/6 Inhibitor Palbociclib<sup>+</sup>
by: Nicla Lorito, et al.
Published: (2020-03-01)

Recent Progress of Palbociclib in Treatment of HR+/HER2- Breast Cancer
by: ZHENG Fangchao, et al.
Published: (2022-07-01)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Yeonhong Lee, et al.
Published: (2023-05-01)

Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021
by: Board Editorial
Published: (2021-12-01)

Novel sequential treatment with palbociclib enhances the effect of cisplatin in RB-proficient triple-negative breast cancer
by: Yajing Huang, et al.
Published: (2020-10-01)

Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism
by: Maysa Abu-Khalaf, et al.
Published: (2022-06-01)

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
by: Adam Brufsky, et al.
Published: (2023-11-01)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
by: Nusayba Bagegni, et al.
Published: (2017-11-01)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
by: Masato Takahashi, et al.
Published: (2020-07-01)

Effectiveness of palbociclib with aromatase inhibitors for the treatment of advanced breast cancer in an exposure retrospective cohort study: implications for clinical practice
by: Filipa Alves da Costa, et al.
Published: (2023-06-01)

Vitiligo-like lesions induced by cyclin-dependent kinase 4/6 inhibitor Palbociclib: a case report and literature review
by: Shan Gao, et al.
Published: (2023-07-01)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
by: Hatice Odabas, et al.
Published: (2023-03-01)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
by: Bernard Royer, et al.
Published: (2021-02-01)

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
by: Wei Wang, et al.
Published: (2024-01-01)

Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
by: François Poumeaud, et al.
Published: (2022-12-01)

Determination of palbociclib by high performance liquid chromatography
by: Xiaodong SHI, et al.
Published: (2017-08-01)

Palbociclib treatment alters nucleotide biosynthesis and glutamine dependency in A549 cells
by: Lindsey R. Conroy, et al.
Published: (2020-07-01)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
by: Adam Brufsky, et al.
Published: (2023-09-01)

Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients
by: Lauren Darrigues, et al.
Published: (2021-03-01)

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In Vivo
by: Lubaid Saleh, et al.
Published: (2023-04-01)

Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study
by: Katie Mycock, et al.
Published: (2022-01-01)

Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2- advanced breast cancer - A Chinese healthcare system perspective
by: Wentao Zhu, et al.
Published: (2023-03-01)

Corrigendum: Severe toxic rhabdomyolysis under combined palbociclib and simvastatin treatment: A case report
by: François Poumeaud, et al.
Published: (2023-02-01)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
by: Katie Mycock, et al.
Published: (2021-01-01)

Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report
by: Vardan Nersesjan, et al.
Published: (2019-10-01)